PM360

DECEMBER 20, 2023

Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. From 2017 to 2022, the Chinese market witnessed a growth rate of 5.3%, compared to the average market growth of 6.6% in the U.S.

Marketing 105

Marketing Insurance Medical Manufacturing 105

Impetus Digital

AUGUST 2, 2024

In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%. Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. Looking back at 2023 , AI for drug discovery saw both wins and losses.

Pharma 95

Pharma Manufacturing Medicine Marketing 95

European Pharmaceutical Review

DECEMBER 18, 2023

Pharmaceutical manufacturing Oligonucleotides Last month, the Centre for Process Innovation (CPI) announced a new Scotland-based manufacturing facility focusing on oligonucleotide therapeutics. ZUMA-7 is the first and largest Phase III study of any CAR T-cell therapy, with the longest follow-up.

Manufacturing 98

Manufacturing Food and Drug Administration Medicine Pharmaceutical manufacturing 98

European Pharmaceutical Review

SEPTEMBER 29, 2022

The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.

Management 97

Management Food and Drug Administration Manufacturing Pharmaceutical manufacturing 97

Medico Reach

FEBRUARY 8, 2023

The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. from 2022 to 2030, the pharma industry will reach USD 9,241.34 billion in 2022 and will expand at a CAGR of 10.3%

Pharma 52

Pharma Medicine Marketing Prospecting 52

Clarivate

MARCH 14, 2024

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.

Pharmaceutical 52

Pharmaceutical Manufacturing Food Healthcare Provider 52

PM360

AUGUST 9, 2022

One reason for this growth is an increasing demand for personalized healthcare technologies as patients look for advances in how healthcare is delivered following the pandemic. NovaXS is on a mission to simplify the medication self-administration process and improve remote healthcare adherence. billion in 2030 at a CAGR of 9.2%.

Prescription 105

Prescription Medical Patients Side effects 105

pharmaphorum

OCTOBER 27, 2022

The Guidance will act as a non-binding and evolving resource for companies and provide additional clarification about communications with healthcare professionals (HCPs), healthcare organisations (HCOs), patient organisations (POs), and other stakeholders, including the general public.

Media 86

Media Pharmaceutical Medicine Electronics 86

European Pharmaceutical Review

AUGUST 10, 2023

Amidst numerous warning letters distributed by the US Food and Drug Administration (FDA) to pharmaceutical manufacturers in recent months, in July this year, the US regulatory body published its analysis on drug product quality in 2022. In subsequent years, up to 2022, half this number or less were issued.

FDA 98

FDA Food and Drug Administration Media Pharmaceutical 98

PM360

APRIL 25, 2023

pharmaceutical industry. Starting with the first adalimumab biosimilar, Amgen’s Amjevita , which launched this January, the healthcare industry is wondering: how broadly will the respective stakeholders see the value and benefits of biosimilar competitors to one of the world’s top selling drugs?

Marketing 97

Marketing Competition Government Manufacturing 97

Pharmaceutical Technology

DECEMBER 19, 2022

in 2022 to 1% in 2023 due to the “tightening of monetary and financial conditions”. Getting funding is going to be more difficult,” says Kyle Faget, partner and co-chair of Foley & Lardner’s Healthcare and Life Sciences Practices, Boston, Massachusetts. It’s going to be a harder environment for smaller and medium biotechs.

Pharmaceutical 69

Pharmaceutical Manufacturing Medicine Government 69

Clarivate

AUGUST 20, 2024

Announced on August 15, 2024, this first batch of Maximum Fair Prices (MFPs) were mandated by the Inflation Reduction Act of 2022 , which allowed CMS to negotiate what it describes as the maximum fair price for therapies representing the greatest cost to Medicare. billion in 2022 , the most recent year for which CMS data is available.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52